Details of the Active Pharmaceutical Ingredient (API)

General Information of API (ID: D00854)
Name
Azelaic acid
Synonyms    Click to Show/Hide the Synonyms of This API
azelaic acid; NONANEDIOIC ACID; 123-99-9; Finacea; Anchoic acid; Azelex; Lepargylic acid; 1,7-Heptanedicarboxylic acid; Skinoren; 1,9-Nonanedioic acid; Heptanedicarboxylic acid; n-Nonanedioic acid; Emerox 1110; Emerox 1144; acide azelaique; Finevin; Azelainic acid; acidum azelaicum; azelate; Polyazelaic anhydride; Skinorem; 1,7-Dicarboxyheptane; Azelaic acid, technical grade; Poly(azelaic anhydride); Emery's L-110; ZK 62498; ZK-62498; UNII-F2VW3D43YT; NSC 19493; Azelaic acid 99%; Azelaic acid, 98%; CHEBI:48131; MFCD00004432; Water-soluble azelaic acid; 26776-28-3; F2VW3D43YT; MLS000069659; azelaate; NSC19493; NSC-19493; NCGC00014993-07; SMR000059164; Acido azelaico; Azalaic Acid; DSSTox_CID_1640; Acide azelaique [French]; Acido azelaico [Spanish]; Acidum azelaicum [Latin]; DSSTox_RID_76254; DSSTox_GSID_21640; heptane-1,7-dicarboxylic acid; Azelaic acid [USAN:INN]; Azelaic polyanhydride; Nonanedioic acid, homopolymer; Azelaic; azelaic-acid; Azelaic acid polyanhydride; 1,9-NONANEDIOIC-D14 ACID; CAS-123-99-9; Finacea (TN); Azelex (TN); SR-01000075671; EINECS 204-669-1; Azelaic acid (USAN/INN); BRN 1101094; Azelaicacidtech; Azelainsaeure; Lepargylate; Nonandisaeure; Anchoate; Nonanedioic acid, sodium salt; n-Nonanedioate; AI3-06299; nonanedionic acid; HSDB 7659; 1tuf; azelaic acid group; 1,9-Nonanedioate; SH-441; AGN-191861; Spectrum_000057; ACMC-1BTAP; Opera_ID_740; Polyazelaic Polyanhydride; 1,7-Heptanedicarboxylate; Spectrum2_000995; Spectrum3_000278; Spectrum4_000401; Spectrum5_001304; C9-120-alpha-polymorph; C9-140-alpha-polymorph; C9-180-alpha-polymorph; C9-220-alpha-polymorph; C9-260-alpha-polymorph; C9-298-alpha-polymorph; Epitope ID:187039; A-9800; EC 204-669-1; Nonanedioic acid homopolymer; Lopac-246379; SCHEMBL3887; CHEMBL1238; Lopac0_000051; BSPBio_001756; KBioGR_000662; KBioSS_000437; Nonanedioic acid Azelaic acid; 4-02-00-02055 (Beilstein Handbook Reference); MLS001148615; ARONIS24596; BIDD:GT0315; DivK1c_000532; SPECTRUM1500648; SPBio_001089; GTPL7484; DTXSID8021640; HMS501K14; KBio1_000532; KBio2_000437; KBio2_003005; KBio2_005573; KBio3_001256; Azelaic acid, analytical standard; NINDS_000532; HMS1921O11; HMS2092E22; HMS2234D10; HMS3260K03; HMS3372J07; Pharmakon1600-01500648; BCP18690; HY-B0704; ZINC1531036; Tox21_110063; Tox21_201989; Tox21_303011; Tox21_500051; ANW-18182; Azelaic acid, technical grade, 80%; CCG-40081; LMFA01170054; NSC757406; s4550; SBB060279; STL059432; AKOS000120052; Tox21_110063_1; Azelaic acid, technical, ~85% (GC); Azelaic acid, Vetec(TM) reagent grade; DB00548; KS-5293; LP00051; LS41867; MCULE-4093240509; NE10317; NSC-757406; SDCCGMLS-0066619.P001; SDCCGSBI-0050040.P004; IDI1_000532; MLS-0066619; NCGC00014993-01; NCGC00014993-02; NCGC00014993-03; NCGC00014993-04; NCGC00014993-05; NCGC00014993-06; NCGC00014993-08; NCGC00014993-09; NCGC00014993-10; NCGC00014993-12; NCGC00014993-15; NCGC00093565-01; NCGC00093565-02; NCGC00093565-03; NCGC00093565-04; NCGC00093565-05; NCGC00093565-06; NCGC00093565-07; NCGC00256508-01; NCGC00259538-01; NCGC00260736-01; 27825-99-6; AK308306; MLS-0066619.P021; SBI-0050040.P003; A0561; Dicarboxylic acid C9; Nonanedioic acid; AZA; EU-0100051; FT-0626920; ST45053319; C08261; D03034; 21175-EP2269988A2; 21175-EP2270008A1; 21175-EP2275413A1; 21175-EP2287156A1; 21175-EP2292617A1; 21175-EP2301940A1; 21175-EP2314295A1; 21175-EP2374895A1; 21175-EP2380874A2; AB00052140_12; Q413504; SR-01000075671-1; SR-01000075671-4; SR-01000075671-6; 0C50D8EC-0DB0-4F24-8EFC-2919E1F0D9BF; Z57127532; F8889-5093; 119176-67-9
Clinical Status
Approved
PubChem CID
2266
Formula
C9H16O4
Canonical SMILES
C(CCCC(=O)O)CCCC(=O)O
InChI
1S/C9H16O4/c10-8(11)6-4-2-1-3-5-7-9(12)13/h1-7H2,(H,10,11)(H,12,13)
InChIKey
BDJRBEYXGGNYIS-UHFFFAOYSA-N
   Click to Show/Hide the Molecular Data (Structure/Property) of This API
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=2266"></iframe>
3D MOL 2D MOL
Physicochemical Properties Molecular Weight 188.22 Topological Polar Surface Area 74.6
XlogP 1.6 Complexity 147
Heavy Atom Count 13 Rotatable Bond Count 8
Hydrogen Bond Donor Count 2 Hydrogen Bond Acceptor Count 4
Full List of Drug Formulations (DFMs) Containing This API
          Azelaic Acid 15% aerosol Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Benzoic Acid; Cetostearyl Alcohol; Dimethyl Isosorbide; Medium-Chain Triglycerides; Methylcellulose; Mono- And Di-Glycerides; Polyoxyl 40 Stearate; Polysorbate 80; Propylene Glycol; Purified Water; Sodium Hydroxide; Xanthan Gum
                   Dosage Form Aerosol
                   Company Leo Pharma As
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Benzoic acid DIG Info FHA-HIT-interacting protein (Ki = 1.9 nM) [1]
Propylene glycol DIG Info Albendazole monooxygenase (Inhibition ratio < 20 %) [2]
Polyoxyl 40 stearate DIG Info Mephenytoin 4-hydroxylase (IC50 = 20.6 uM) [3]
Polysorbate 80 DIG Info Prostaglandin G/H synthase 1 (IC50 = 1 uM) [4]
Medium-chain triglyceride DIG Info Colon cancer Caco-2 cells (Inhibition ratio > 36 %) [5]
          Azelaic Acid 15% gel Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Benzoic Acid; Edetate Disodium; 1, 2-Diarachidoyl-Sn-Glycero-3-Phosphocholine; Medium-Chain Triglycerides; Polyacrylic Acid (250000 Mw); Polysorbate 80; Propylene Glycol; Sodium Hydroxide; Water
                   Dosage Form Gel
                   Company A-S Medication Solutions
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Benzoic acid DIG Info FHA-HIT-interacting protein (Ki = 1.9 nM) [1]
Propylene glycol DIG Info Albendazole monooxygenase (Inhibition ratio < 20 %) [2]
Polysorbate 80 DIG Info Prostaglandin G/H synthase 1 (IC50 = 1 uM) [4]
Medium-chain triglyceride DIG Info Colon cancer Caco-2 cells (Inhibition ratio > 36 %) [5]
          Azelaic Acid 20% cream Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Cetearyl Octanoate; Glycerin; Glyceryl Stearate; Cetearyl Alcohol; Cetyl Palmitate; Cocoglycerides; Peg-5 Glyceryl Stearate; Propylene Glycol; Purified Water
                   Dosage Form Cream
                   Company Almirall
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Glyceryl monostearate DIG Info Prostate cancer LNCaP cells (IC50 > 100000 nM) [6]
Propylene glycol DIG Info Albendazole monooxygenase (Inhibition ratio < 20 %) [2]
References
1 WO patent application no. 2017162840A1, SENSITIZATION OF CANCER CELLS TO NAMPT INHIBITORS BY NICOTINIC ACID PHOSPHORIBOSYLTRANSFERASE NEUTRALIZATION.
2 Pharmaceutical excipients inhibit cytochrome P450 activity in cell free systems and after systemic administration. Eur J Pharm Biopharm. 2008 Sep;70(1):279-88.
3 Effects of polyoxyethylene (40) stearate on the activity of P-glycoprotein and cytochrome P450. Eur J Pharm Sci. 2009 Jul 12;37(5):573-80.
4 The activities of drug inactive ingredients on biological targets. Science. 2020 Jul 24;369(6502):403-413.
5 Interactions between human multidrug resistance related protein (MRP2; ABCC2) and excipients commonly used in self-emulsifying drug delivery systems (SEDDS). Int J Pharm. 2013 Apr 15;447(1-2):192-8.
6 Lignanamides and nonalkaloidal components of Hyoscyamus niger seeds. J Nat Prod. 2002 Feb; 65(2):206-9.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.